# Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

> **NCT05667597** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Maria Goossens** · enrollment: 350 (actual)

## Conditions studied

- SARS CoV 2 Infection
- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** Humoral immunity

## Key facts

- **NCT ID:** NCT05667597
- **Lead sponsor:** Maria Goossens
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667597, "Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05667597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*